% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Stocker:212457,
author = {H. Stocker$^*$ and L. Beyer and K. Trares$^*$ and L. Perna
and D. Rujescu and B. Holleczek and K. Beyreuther and K.
Gerwert and B. Schöttker$^*$ and H. Brenner$^*$},
title = {{A}ssociation of {K}idney {F}unction {W}ith {D}evelopment
of {A}lzheimer {D}isease and {O}ther {D}ementias and
{D}ementia-{R}elated {B}lood {B}iomarkers.},
journal = {JAMA network open},
volume = {6},
number = {1},
issn = {2574-3805},
address = {Chicago, Ill.},
publisher = {American Medical Association},
reportid = {DKFZ-2023-00174},
pages = {e2252387 -},
year = {2023},
note = {#EA:C070#LA:C070#},
abstract = {Previous research has suggested an association of kidney
function with risk of Alzheimer disease (AD) or other
dementias and dementia-related blood biomarkers, but a
distinct association remains unclear.To evaluate the
association of kidney function with risk of diagnosis of
incident AD or dementia within 17 years and with the blood
biomarkers neurofilament light (NfL), phosphorylated tau181
(p-tau181), and glial fibrillary acidic protein (GFAP).In
this prospective, population-based cohort study and nested
case-control study, 9940 participants in Germany were
enrolled between 2000 and 2002 by their general
practitioners and followed up for up to 17 years.
Participants were included if information on dementia status
and creatinine/cystatin C measurements were available. A
subsample of participants additionally had measurements of
NfL, p-tau181, and GFAP obtained from blood samples.
Statistical analysis was performed from January 3 to
November 25, 2022.Impaired kidney function, based on
estimated glomerular filtration rate less than 60
mL/min/1.73 m2 according to the 2021 Chronic Kidney Disease
Epidemiology Collaboration creatinine-cystatin C
equation.All-cause dementia, AD, and vascular dementia
diagnosis, as well as log-transformed levels of NfL,
p-tau181, and GFAP in blood.Of 6256 participants (3402 women
$[54.4\%];$ mean [SD] age at baseline, 61.7 [6.6] years),
510 received an all-cause dementia diagnosis within 17 years
of baseline. The dementia-related blood biomarker nested
case-control sample included 766 participants. After
adjusting for age and sex, impaired kidney function at
baseline was not associated with a higher risk of all-cause
dementia (hazard ratio [HR], 0.95; $95\%$ CI, 0.69-1.29), AD
(HR, 0.94; $95\%$ CI, 0.55-1.63), or vascular dementia
diagnosis (HR, 1.06; $95\%$ CI, 0.65-1.70) within 17 years.
In the cross-sectional analysis, after adjusting for age and
sex, impaired kidney function was significantly associated
with NfL and p-tau181 levels in blood (NfL: β = 0.47 and P
< .001; p-tau181: β = 0.21 and P = .003). After adjusting
for age and sex, significant associations with GFAP levels
were evident only among men (men: β = 0.31 and P = .006;
women: β = -0.12 and P = .11).In this population-based
study of community-dwelling adults, reduced kidney function
was associated with increased levels of dementia-related
blood biomarkers but not increased dementia risk. Kidney
function might influence the accuracy of dementia-related
blood biomarkers and should be considered in clinical
translation.},
cin = {C070},
ddc = {610},
cid = {I:(DE-He78)C070-20160331},
pnm = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
pid = {G:(DE-HGF)POF4-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:36692879},
doi = {10.1001/jamanetworkopen.2022.52387},
url = {https://inrepo02.dkfz.de/record/212457},
}